Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line.

Lupo MG, Biancorosso N, Brilli E, Tarantino G, Adorni MP, Vivian G, Salvalaio M, Dall'Acqua S, Sut S, Neutel C, Chen H, Bressan A, Faggin E, Rattazzi M, Ferri N.

Nutrients. 2020 Feb 9;12(2). pii: E436. doi: 10.3390/nu12020436.

2.

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.

Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, Arribas AJ, Cascione L, Bigioni M, Merlino G, Fiascarelli A, Bressan A, Mensah AA, Golino G, Lucchini R, Bernasconi E, Rossi D, Zucca E, Stussi G, Stathis A, Boyd RS, Dusek RL, Bisht A, Attanasio N, Rohlff C, Pellacani A, Binaschi M, Bertoni F.

Haematologica. 2020 Jan 9. pii: haematol.2019.227215. doi: 10.3324/haematol.2019.227215. [Epub ahead of print]

3.

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.

Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M.

Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21.

PMID:
31227646
4.

OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain.

Bressan A, Bozzo F, Maggi CA, Binaschi M.

Dis Markers. 2013;34(4):257-67. doi: 10.3233/DMA-130968.

5.

SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.

Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M.

Int J Oncol. 2012 Oct;41(4):1486-94. doi: 10.3892/ijo.2012.1551. Epub 2012 Jul 13.

PMID:
22797667
6.

Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships of α,α-tetrahydropyranylglycine.

Fincham CI, Bressan A, D'Andrea P, Ettorre A, Giuliani S, Mauro S, Meini S, Paris M, Quartara L, Rossi C, Squarcia A, Valenti C, Daniela F, Maggi CA.

Bioorg Med Chem. 2012 Mar 15;20(6):2091-100. doi: 10.1016/j.bmc.2012.01.036. Epub 2012 Jan 30.

PMID:
22342268
7.

Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.

Bressan A, Bigioni M, Bellarosa D, Nardelli F, Irrissuto C, Maggi CA, Binaschi M.

Oncol Rep. 2010 Nov;24(5):1249-55.

PMID:
20878117
8.

Bradykinin receptor antagonists--a review of the patent literature 2005-2008.

Fincham CI, Bressan A, Paris M, Rossi C, Fattori D.

Expert Opin Ther Pat. 2009 Jul;19(7):919-41. doi: 10.1517/13543770902994389. Review.

PMID:
19552510
9.

Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

Bigioni M, Parlani M, Bressan A, Bellarosa D, Rivoltini L, Animati F, Crea A, Bugianesi R, Maggi CA, Manzini S, Binaschi M.

Int J Cancer. 2009 Nov 15;125(10):2456-64. doi: 10.1002/ijc.24661.

10.

Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.

Bressan A, Nardelli F, Bellarosa D, Bigioni M, Curcurù G, Curatella B, Crea A, Maggi CA, Manzini S, Binaschi M.

Anticancer Res. 2007 Nov-Dec;27(6B):4039-46.

11.

Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 2. Synthesis and structure-activity relationships of alpha,alpha-cycloalkylglycine sulfonamides.

Fattori D, Rossi C, Fincham CI, Caciagli V, Catrambone F, D'Andrea P, Felicetti P, Gensini M, Marastoni E, Nannicini R, Paris M, Terracciano R, Bressan A, Giuliani S, Maggi CA, Meini S, Valenti C, Quartara L.

J Med Chem. 2007 Feb 8;50(3):550-65.

PMID:
17266207
12.

Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of alpha,alpha-dimethylglycine sulfonamides.

Fattori D, Rossi C, Fincham CI, Berettoni M, Calvani F, Catrambone F, Felicetti P, Gensini M, Terracciano R, Altamura M, Bressan A, Giuliani S, Maggi CA, Meini S, Valenti C, Quartara L.

J Med Chem. 2006 Jun 15;49(12):3602-13.

PMID:
16759102
13.

MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.

Cucchi P, Meini S, Bressan A, Catalani C, Bellucci F, Santicioli P, Lecci A, Faiella A, Rotondaro L, Giuliani S, Giolitti A, Quartara L, Maggi CA.

Eur J Pharmacol. 2005 Dec 28;528(1-3):7-16. Epub 2005 Dec 1.

PMID:
16324696
14.

ARS Component B: structural characterization, tissue expression and regulation of the gene and protein (SLURP-1) associated with Mal de Meleda.

Mastrangeli R, Donini S, Kelton CA, He C, Bressan A, Milazzo F, Ciolli V, Borrelli F, Martelli F, Biffoni M, Serlupi-Crescenzi O, Serani S, Micangeli E, El Tayar N, Vaccaro R, Renda T, Lisciani R, Rossi M, Papoian R.

Eur J Dermatol. 2003 Nov-Dec;13(6):560-70.

PMID:
14721776
15.

Expression and characterization of biologically active human Fas ligand produced in CHO cells.

Zappitelli S, D'Alatri L, Ciucci A, Raucci G, Faiella A, Gabrielli M, Parlani M, Bressan A, Maggi CA, Goso C, Rotondaro L.

Mol Biotechnol. 2003 Mar;23(3):189-202.

PMID:
12665690

Supplemental Content

Loading ...
Support Center